Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (January 2024)
35 slides from Immunome's investor presentation, Jan 11, 2024
Slide 1: Immunome Corporate Presentation
Immunome Corporate Presentation January 11, 2024
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Immunome, Inc. (“Immunome”) or any person on its behalf, any question-
Slide 3: Establishing a Premier Targeted Oncology Company
Establishing a Premier Targeted Oncology Company Long-Term Corporate Vision Strong Foundation for Long-Term Success • Experienced, successful leadership team whose • Develop first-in-class and best-in-class members have developed approved oncology oncology therapies therapeutics across multiple moda
Slide 4: Recent Business Development Activity Expanded Pipeline and Toolbox With Moderate Investment
Recent Business Development Activity Expanded Pipeline and Toolbox With Moderate Investment • Exclusive license of ADC assets • Preclinical ROR1 ADC with best-in-class potential • Purchase of assets related to over 25 preclinical antibodies • Differentiated ADC platform technology • Opportunity to p
Slide 5: Pipeline and Discovery Overview
Pipeline and Discovery Overview Lead Development Anticipated Target Candidate Modality Discovery IND-Enabling Optimization Candidate IND Filing FAP Undisclosed RLT 1Q2025 ROR1 IM-10211 ADC 1Q2025 IL-38 IM-43202 Immunotherapy 1Q2025 Undisclosed - ADC TBD Undisclosed - RLT TBD 1. Formerly known as ZPC
Slide 6: ADC Strategy
ADC Strategy IMMUNOME 6
Slide 7: Target-Driven Development For the Next Generation of ADCs
Target-Driven Development For the Next Generation of ADCs Immunome Approach Systematic Development Through Clinical Proof of Concept • Focus on oncology indications with high unmet need Optimization for binding & internalization • Identify novel or underexplored targets that are suitable for ADCs an
Slide 8: ADC Activity is Concentrated in a Small Number of Targets
ADC Activity is Concentrated in a Small Number of Targets Top 10 Targets Account for 54% of Active Clinical ADC Downsides of Pursuing Most Popular Targets Programs • Limitations of existing drugs may be difficult to overcome Approved ADC • Performance of current drugs may be limited by Active Clinic
Slide 9: Systematically Evaluate Novel Targets for First-in-Class ADC Potential
Systematically Evaluate Novel Targets for First-in-Class ADC Potential Targets are evaluated for differential tumor expression and Sources of Novel Targets and additional considerations Antibodies Solid Tumor ADCs Immunome Discovery Tivdak Platform Trodelvy >30 identified targets Tumor Expression El
Slide 10: Proprietary Payload Provides Opportunity to Develop Best-in-Class ADCs
Proprietary Payload Provides Opportunity to Develop Best-in-Class ADCs Proprietary ADC Payload HER2 ADC Constructed with IMNM Proprietary Payload Outperforms Enhertu in JIMT-1 Breast Cancer Model • Camptothecin derivative/TOPO1 inhibitor • Same class as Enhertu payload deruxtecan (DXd) 3000 Vehiclec
Slide 11: Camptothecin Derivatives Are Well-Suited for ADCs Targeting Solid Tumors
Camptothecin Derivatives Are Well-Suited for ADCs Targeting Solid Tumors $175m Derivative Payload) Enhertu (With Camptothecin ADCs Containing Camptothecins Achieve Higher DARs and Higher Clinical Doses Outperforms Kadcyla in Breast Cancer3 Progression-Free Survival 12 Clinical Doses of Selected ADCs
Slide 12: Strong Demand for ADCs Provides Strategic Flexibility
Strong Demand for ADCs Provides Strategic Flexibility Opportunities to Transact at Value Inflection Points Recent ADC Transactions $170 million $4 billion upfront3 upfront $2 billion total1 $1.5 billion+ $22 billion in milestones in milestones5 $43 billion acquisition7 $175 million $85 million upfro
Slide 13: Immunome Discovery Platform
Immunome Discovery Platform IMMUNOME 13
Slide 14: Antibody and Target Discovery Engine
Antibody and Target Discovery Engine Harnessing the Immune System to Inform the Next Generation of Cancer Therapy Patient responses unveil novel disease targets 01 02 03 04 Patients with cancer Memory B cells are Antibodies are selected Novel antibody-target generate memory B cells isolated, and imm
Slide 15: Immunome Approach Identifies Both Validated and Novel Cancer Targets
Immunome Approach Identifies Both Validated and Novel Cancer Targets Identification of Clinically Validated Cancer Immunome Technology Enhances Power Targets Validates Immunome Approach of Antibody Screens Target-specific Literature • Memory B-cell response generated across course Known Unknown 4000
Slide 16: Strategic Discovery Collaboration with AbbVie
Strategic Discovery Collaboration with AbbVie Key Financial Terms • AbbVie option to purchase worldwide rights for up to 10 novel target-antibody pairs arising from three specified tumor types • $30M upfront payment • Eligible for additional payments up to: ‒ $70M platform access payments (in additi
Slide 17: Programs: ROR1 ADC
Programs: ROR1 ADC IMMUNOME 17
Slide 18: ROR1 ADC Achieved Objective Responses in Clinical Trial
ROR1 ADC Achieved Objective Responses in Clinical Trial MK-2140 Objective Response Rate In Three Pretreated Lymphoma Indications ROR1 • Receptor with oncofetal expression pattern1 • Little or no expression in healthy tissue 60% • Expressed on solid and liquid tumors 50% 14% PR CR 12% 40% MK-2140 • M
Slide 19: Significant Opportunity for ROR1 in Solid Tumors
Significant Opportunity for ROR1 in Solid Tumors Potential ROR1 indications include ROR1 target biology presents challenges to diseases with large patient population developing a successful ADC for ROR1 and high unmet need positive solid tumors • Moderate to low expression levels • Slow internalizat
Slide 20: IM-1021 is a ROR1 ADC with Potential for Improved Therapeutic Index
IM-1021 is a ROR1 ADC with Potential for Improved Therapeutic Index Name Linker / DAR Payload Development Status Zilovertamab Vedotin (MK-2140 / VLS-101) MMAE: Tubulin Inhibitor Phase 2 completed; no MC-VC-PAB further updates Cysteine conjugation Cleavable through Val-Cit DAR 4 NBE-002 Peptide linke
Slide 21: IM-1021 Shows Sustained Tumor Regression in TNBC Mouse Model
IM-1021 Shows Sustained Tumor Regression in TNBC Mouse Model IM-1021 Inhibits Tumor Growth in MDA-MB-468 Model No Weight Loss Observed (Triple Negative Breast Cancer) 1200 Vehicle qw × 3 30 Vehicle ATX875-1-5379 (2.5 mg/kg qw×3) IM-1021 2.5 mg/kg Tumor Volume (mm3) ATX875-1-5379 (5.0 mg/kg qw×3) 20
Slide 22: Clinical Development Plan: Rapid Evaluation of Clinical PoC Followed by Pivotal Studies
Clinical Development Plan: Rapid Evaluation of Clinical PoC Followed by Pivotal Studies Across Multiple Indications Solid tumor expansion Indications including NSCLC, breast cancer, prostate cancer, pancreatic Pivotal studies as indicated cancer, and gastric cancer1 Rapid dose escalation in • Compel
Slide 23: Programs: FAP RLT
Programs: FAP RLT IMMUNOME 23
Slide 24: FAP Is a Promising RLT Target with Pan-Cancer Potential
FAP Is a Promising RLT Target with FAP imaging shows high expression across Pan-Cancer Potential 15 distinct tumor types • Fibroblast Activation Protein (FAP) is a cell surface protease with low expression in normal tissue • FAP is overexpressed on cancer-associated fibroblasts, the most common tumo
Slide 25: Immunome 177Lu-FAP Candidates are Rationally Designed and Systematically Screened
Immunome 177Lu-FAP Candidates are Rationally Immunome Approach Designed and Example Proven structure used by Pluvicto and Lutathera to Systematically Screened Structure: Optimized linker reduces non- specific uptake deliver Lu-177 isotope Chelator FAP Ligand O H N O Linker HOOC N N COOH Immunome has
Slide 26: Incorporating Albumin Binders into Radioligand Therapies Improves In Vivo PK Profile
Incorporating Albumin Binders into Radioligand Therapies Improves In Vivo PK Profile and Biodistribution Total Absorbed Dose Rat IV PK 600 100000 Albumin Binding Albumin Binding Weak Weak 10000 500 Moderate concentration Moderate Plasmaconcentration 1000 Strong 400 Strong (ng/ mL) (ng/mL) mGy/MBq 10
Slide 27: Developing 177Lu-FAP Candidates with Best-in-Class Potential
Developing 177Lu-FAP Candidates with Best-in-Class Potential In vivo data show single dose antitumor activity and tolerability Tumor Regression in U87MG Model 177 Noi-003 Weight Loss Observed Stab Characteristics Potential Best-in-Class 177 Lu-M Radiotherapy in U87M G tumors Lu-M i-003 Radiotherapy
Slide 28: Programs: IL-38 Immunotherapy
Programs: IL-38 Immunotherapy IMMUNOME 28
Slide 29: IL-38 Is an Immunosuppressive Cytokine with I/O Potential
IL-38 Is an Immunosuppressive Cytokine with I/O Potential IL-38 Function: Inhibits pro-inflammatory IL-36/IL-36R pathway1 Scientific Rationale: Downregulation of IL-38 promotes innate immune activation • IL-38 knockout mice exhibit increased pro-inflammatory cytokine levels2 and delayed tumor growth
Slide 30: Poor Survival for Cancer Patients with Tumors Expressing High IL-38
Poor Survival for Cancer Patients with Tumors Expressing High IL-38 Reduced Immune Cell Infiltration in IL-38 High Tumors Poor Overall Survival in IL-38 High Lung Cancer Key T Cells B Cells Kaplan-Meier curves according to IL-38 expression in HNSC HNSC HNSC patients with primary lung adenocarcinoma
Slide 31: IM-4320: Platform-Derived, Potential First-in-Class IL-38 mAb
IM-4320: Platform-Derived, Potential First-in-Class IL-38 mAb Inhibits IL-38-mediated immunosuppression IM-4320 Selectively Binds IL-38 IM-4320 Inhibits IL-38 Binding IM-4320 Inhibits Tumor Growth in Mice 100 5000 1st dose IL-38 2000 SEM(mm3) (mm ) 3 Vehicle 80 4000 Anti-CTLA4 - 10 mg/ kg IL-38 ofIL
Slide 32: IP, Business Development, and Leadership
IP, Business Development, and Leadership IMMUNOME 32
Slide 33: Prosecuting a Multi-Layered IP Strategy
Prosecuting a Multi-Layered IP Strategy COMPOSITION OF MATTER • Over 100 patents and patent applications across more than 20 families as of November 2023 • Covers Immunome’s proprietary PLATFORM & DISCOVERY antibody sequences • Platform technologies and • Covers proprietary targeting discovery engin
Slide 34: Management Team with a Demonstrated Track Record of Success
Management Team with a Demonstrated Track Record of Success Clay Siegall, Ph.D. • Chief Executive Officer and Founder, Seagen (1998-2022) President & Chief • Grew company to $2B+ revenue (2022) leading to $43B acquisition Executive Officer • Led development of 4 FDA-approved therapeutics • Raised ov
Slide 35: Building the Foundation of a Premier Targeted Oncology Company
Building the Foundation of a Premier Targeted Oncology Company • Experienced management team with headquarters in Bothell, WA • Focused on developing best-in-class or first-in-class targeted oncology therapies including next-generation ADCs and RLTs • Three lead programs with best-in-class or first-